582 related articles for article (PubMed ID: 30230584)
1. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
Ho PH; Tsai TF
J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
[TBL] [Abstract][Full Text] [Related]
3. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab.
Pan J; Qiu L; Xiao T; Chen HD
Dermatol Ther; 2016 May; 29(3):164-7. PubMed ID: 26627198
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
5. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis.
López-Sánchez C; Falla LM; Roé-Crespo E; Arostegui JI; Mozos A; Bernal S; Iznardo H; Baselga-Torres E
J Dermatol; 2021 Jun; 48(6):907-910. PubMed ID: 33543522
[TBL] [Abstract][Full Text] [Related]
6. Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia.
Lau BW; Lim DZ; Capon F; Barker JN; Choon SE
Int J Dermatol; 2017 Apr; 56(4):392-399. PubMed ID: 28194751
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy.
Zhu H; Song P; Du D; Tian H
Pediatr Dermatol; 2021 Sep; 38(5):1366-1367. PubMed ID: 34515373
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation of IL36RN.
Koike Y; Okubo M; Kiyohara T; Fukuchi R; Sato Y; Kuwatsuka S; Takeichi T; Akiyama M; Sugiura K; Utani A
Br J Dermatol; 2017 Dec; 177(6):1732-1736. PubMed ID: 28369922
[TBL] [Abstract][Full Text] [Related]
9. Use of biologics in Chinese pregnant patients with deficiency of interleukin-36 receptor antagonist (DITRA): A case series.
Hsieh CY; Tsai YJ; Tsai TF
Taiwan J Obstet Gynecol; 2024 May; 63(3):405-408. PubMed ID: 38802208
[TBL] [Abstract][Full Text] [Related]
10. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.
Komatsuda S; Kamata M; Chijiwa C; Namiki K; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Abe K; Yamamoto T; Aozasa N; Sugiura K; Tada Y
J Dermatol; 2019 Jan; 46(1):73-75. PubMed ID: 30474867
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
14. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis.
Zhu T; Jin H; Shu D; Li F; Wu C
Eur J Dermatol; 2018 Apr; 28(2):217-224. PubMed ID: 29619998
[TBL] [Abstract][Full Text] [Related]
15. Clinical advances in biological therapy for generalized pustular psoriasis: a review.
Hsieh CY; Tsai TF
Expert Opin Biol Ther; 2024; 24(1-2):37-50. PubMed ID: 38247394
[TBL] [Abstract][Full Text] [Related]
16. Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement.
Jing G; Bin W; Ying ZZ
Pediatr Dermatol; 2021 Sep; 38(5):1258-1263. PubMed ID: 34339530
[TBL] [Abstract][Full Text] [Related]
17. Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: A PRISMA-compliant systematic review and meta-analysis.
Liu ZJ; Tian YT; Shi BY; Zhou Y; Jia XS
Medicine (Baltimore); 2020 Nov; 99(45):e23068. PubMed ID: 33157966
[TBL] [Abstract][Full Text] [Related]
18. Successful therapy with secukinumab in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation.
Gabeff R; Safar R; Leducq S; Maruani A; Sarrabay G; Touitou I; Samimi M
Int J Dermatol; 2019 Jan; 58(1):e16-e17. PubMed ID: 30430544
[No Abstract] [Full Text] [Related]
19. Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes.
Wang Y; Cheng R; Lu Z; Guo Y; Yan M; Liang J; Huang P; Li M; Yao Z
J Dermatol Sci; 2017 Mar; 85(3):235-240. PubMed ID: 28063630
[TBL] [Abstract][Full Text] [Related]
20. Acquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?
Hsu FL; Hsieh CY; Tsai TF
Exp Dermatol; 2024 Mar; 33(3):e15056. PubMed ID: 38488485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
